VPS35 and Parkinson disease: Pathogenic mutations in other Parkinson’s disease genes, including Rab32 and VPS35, also enhance LRRK2 signaling, underscoring the importance of understanding how upstream cellular processes regulate LRRK2 activation (Gustavsson et al., 2024; Hop et al., 2024; McCarron et al., 2024; Mir et al., 2018).